A phase ii study of carboplatin in nasopharyngeal carcinoma

Kwan H. Chi*, Yuan C. Chang, Wing K. Chan, Jacqueline M. Liu, Chi K. Law, Su S. Lo, Chih H. Shu, Shan H. Yen, Jacqueline Whang-Peng, Kuang Y. Chen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44%) patients had a partial response with a 95% confidence interval of 26-62%. Fifteen (47%) patients had stable disease and 3 (9%) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12%) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalOncology (Switzerland)
Issue number3
StatePublished - 1 Jan 1997


  • Carboplatin
  • Nasopharyngeal carcinoma
  • Phase II study


Dive into the research topics of 'A phase ii study of carboplatin in nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this